Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Free Cash Flow (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Free Cash Flow for 3 consecutive years, with -$1.9 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Free Cash Flow fell 35.26% year-over-year to -$1.9 million, compared with a TTM value of -$8.4 million through Dec 2024, up 20.09%, and an annual FY2024 reading of -$8.4 million, up 20.09% over the prior year.
  • Free Cash Flow was -$1.9 million for Q4 2024 at Oramed Pharmaceuticals, up from -$7.1 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $2.1 million in Q2 2024 and bottomed at -$9.2 million in Q1 2022.
  • Average Free Cash Flow over 3 years is -$3.9 million, with a median of -$2.5 million recorded in 2022.
  • Peak annual rise in Free Cash Flow hit 178.22% in 2024, while the deepest fall reached 878.79% in 2024.
  • Year by year, Free Cash Flow stood at -$8.4 million in 2022, then skyrocketed by 83.02% to -$1.4 million in 2023, then plummeted by 35.26% to -$1.9 million in 2024.
  • Business Quant data shows Free Cash Flow for ORMP at -$1.9 million in Q4 2024, -$7.1 million in Q3 2024, and $2.1 million in Q2 2024.